Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803
about
Prognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature ReviewMolecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and diseaseSerrated colorectal cancer: Molecular classification, prognosis, and response to chemotherapyToward a Molecular Classification of Colorectal Cancer: The Role of BRAFBRAFV600E mutation and its association with clinicopathological features of colorectal cancer: a systematic review and meta-analysis.The biological complexity of colorectal cancer: insights into biomarkers for early detection and personalized careEstablishment, characterization and chemosensitivity of three mismatch repair deficient cell lines from sporadic and inherited colorectal carcinomasColorectal Cancer Classification and Cell Heterogeneity: A Systems Oncology ApproachBRAF mutations: signaling, epidemiology, and clinical experience in multiple malignancies.BRAFV600E immunohistochemistry in conjunction with mismatch repair status predicts survival in patients with colorectal cancer.Family history of colorectal cancer in BRAF p.V600E-mutated colorectal cancer cases.KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance).Current status of gene expression profiling to assist decision making in stage II colon cancerA very low incidence of BRAF mutations in Middle Eastern colorectal carcinoma.CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer.Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies.SMO expression in colorectal cancer: associations with clinical, pathological, and molecular featuresChromosomal instability in BRAF mutant, microsatellite stable colorectal cancers.Prognostic Impact of Deficient DNA Mismatch Repair and Mutations in KRAS, and BRAF(V600E) in Patients with Lymph Node-Positive Colon CancerColorectal carcinoma: Pathologic aspectsMolecular markers identify subtypes of stage III colon cancer associated with patient outcomesProgression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancerMutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive valueAssociation between molecular subtypes of colorectal cancer and patient survivalBRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch syndromePrognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy.High nuclear/cytoplasmic ratio of Cdk1 expression predicts poor prognosis in colorectal cancer patients.Colorectal cancers from distinct ancestral populations show variations in BRAF mutation frequencyContext-dependent interpretation of the prognostic value of BRAF and KRAS mutations in colorectal cancer.Prognostic value of KRAS and BRAF mutations in curatively resected colorectal cancerMicrosatellite stable colorectal cancers stratified by the BRAF V600E mutation show distinct patterns of chromosomal instability.Performance comparison of three BRAF V600E detection methods in malignant melanoma and colorectal cancer specimens.Influence of microsatellite instability and KRAS and BRAF mutations on lymph node harvest in stage I-III colon cancers.Microsatellite instability and mutations in BRAF and KRAS are significant predictors of disseminated disease in colon cancer.PIK3CA mutations predict recurrence in localized microsatellite stable colon cancerLack of Association between Membrane-Type 1 Matrix Metalloproteinase Expression and Clinically Relevant Molecular or Morphologic Tumor Characteristics at the Leading Edge of Invasive Colorectal Carcinoma.Detection of KRAS, NRAS and BRAF by mass spectrometry - a sensitive, reliable, fast and cost-effective techniqueMethylation changes in the TFAP2E promoter region are associated with BRAF mutation and poorer overall & disease free survival in colorectal cancer.Prognostic Role of BRAF Mutation in Stage II/III Colorectal Cancer Receiving Curative Resection and Adjuvant Chemotherapy: A Meta-Analysis Based on Randomized Clinical Trials.CpG Island Methylation, Microsatellite Instability, and BRAF Mutations and Their Clinical Application in the Treatment of Colon Cancer.
P2860
Q24289005-44DCA6EB-9288-47A9-91B3-97AE1DD08DCAQ24289344-583B5EA2-DA89-488B-89A6-D37CDC1AF4CEQ26751035-A8F0CF96-5336-4781-ACC5-1C10599B82C0Q26827212-60777AF3-25B4-4F42-B1EE-43754B579DF4Q27852942-C1402F85-0A6F-4858-B6B3-476DDD4978BBQ28066460-A4E1B774-4C6E-4972-B49F-512CEA3AEB29Q28484668-3DB82497-CDFA-4175-9CC3-78D45B2F3EA7Q28647615-FEC85B1E-C877-43A7-B4EC-69B038BED0AEQ30458424-E3AEEC82-8CB1-4073-A35E-CE0BAC12A23DQ33615076-242B7328-FEA2-44DE-8FFD-E513FB177E11Q33625221-CC004B76-1D98-44AE-8291-2A09FD1EB226Q33693309-E552948C-8134-473A-A8AA-58DD6DCB3C48Q33829763-FA673DAB-BE92-4768-B844-4A9879AA3A53Q33945376-8D4972E0-EE07-40F8-B1E9-EE3CA8EBCA61Q34084652-DAF02138-8202-4D26-B829-0357F3E21794Q34362289-E1737C6E-9269-43E4-8A19-4A284AAD1CD0Q34458644-EAEB4BD6-62D6-4D17-912E-70257E9FE39FQ34460444-BBE4295B-9298-4E4E-BC5F-7E31EBE99D79Q34472453-A290D6D2-9EDF-4BF1-BC45-718E0B8559FEQ34642007-3433F5B4-5A0F-4F75-A8E4-8CF5F64F11C6Q34665492-BA1E75EB-7701-4CFF-A5DA-FA22F1FC1978Q34703562-82469BC8-33FA-4B7E-97E8-A045A51BD9E5Q34755943-14E9EF0D-E77D-4939-889E-D93312DB7D6BQ34759064-AB2E6DF7-58DF-4A1A-AD4B-111F97690E5BQ34782265-0BE16BAE-0B10-4118-9174-4785B61C3775Q34982575-5E205C9C-274F-4BCF-AA76-C8CC47EC1A4BQ34996366-DD53540A-0DB4-4972-9CAE-1DE8E637C2C4Q34997425-2FCB5065-99DC-4AD2-9A91-BA92E14E8A1DQ35001203-F6356817-9F2D-4D47-8EAA-B0566A852EDFQ35012132-544B4E94-70F3-45DA-B2CB-1DCD11368573Q35126713-D9428078-1D8A-4081-A94A-C35343945414Q35126758-006697B5-CA09-4DBB-B905-E37F294643A9Q35130874-79635B7B-0C9B-4C58-8719-DE9262726126Q35191237-F94FF04E-F4E6-4C66-8BDB-6D7C4618C5C9Q35236785-049277D3-2896-4DDF-835E-9724D140C145Q35708122-5A37B987-7B90-4D03-8530-31E3E1D4B2B6Q35721438-D43BF3EA-CFE8-44E0-9980-77C080FB4BBEQ35745033-8AC28743-FC28-44D3-8E39-E76BDE6D510DQ36006605-19B645ED-4ED3-42CE-84EF-87FD3784F13DQ36075933-F05EBF1A-EE27-4D98-832F-205364DB0711
P2860
Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Predictive and prognostic role ...... m intergroup trial CALGB 89803
@ast
Predictive and prognostic role ...... m intergroup trial CALGB 89803
@en
type
label
Predictive and prognostic role ...... m intergroup trial CALGB 89803
@ast
Predictive and prognostic role ...... m intergroup trial CALGB 89803
@en
prefLabel
Predictive and prognostic role ...... m intergroup trial CALGB 89803
@ast
Predictive and prognostic role ...... m intergroup trial CALGB 89803
@en
P2093
P2860
P50
P1476
Predictive and prognostic role ...... m intergroup trial CALGB 89803
@en
P2093
Al B Benson
Alexander Hantel
Donna Hollis
Kaori Shima
Leonard B Saltz
Monica M Bertagnolli
Nadine J McCleary
Paul Schaefer
Renaud Whittom
P2860
P304
P356
10.1158/1078-0432.CCR-11-2246
P407
P577
2011-12-06T00:00:00Z